- BrightView Holdings Inc (NYSE:BV) Board authorized a share repurchase program totaling $250 million. The program has no time limit.
- The buyback is effective immediately and allows for ongoing and profitable investment in the business while utilizing moderate balance sheet leverage and facilitating opportunistic share repurchases.
- The company says the share repurchase authorization announced does not affect its previously stated and ongoing mergers and acquisitions strategy.
- BrightView held $123.7 million in cash and equivalents as of September 30, 2021.
- Price Action: BV shares closed lower by 1.10% at $13.46 on Friday.
Knight Therapeutics Announces Health Canada Approval For NERLYNX To Treat HER2-Positive Metastatic Breast Cancer
Knight Therapeutics Inc. (TSX:GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine
